ALK and adenocarcinoma: The impact of chemotherapy on ALK+ NSCLC is modest, even though this disease seems to be more sensitive to pemetrexed-based regimens with respect to ALK- NSCLC [23,24,25], maybe due to the fact that ALK+ adenocarcinoma has the lowest levels of thymidylate synthase [25,26,27].